logo
Plus   Neg
Share
Email

Blackstone To Change From Partnership To Corporation; Q1 Profit Up 34%

Blackstone (BX) announced conversion from a publicly traded partnership to a corporation, expected to be effective July 1, 2019. The company said this paves the way for equity value appreciation by removing ownership restrictions and by expanding global investor universe. Blackstone expects the conversion to produce significant potential benefit at relatively modest additional tax cost. Estimated annual dilution to distributable earnings per common share is approximately 2-5% on an average over the next 5 years. Over the longer term, the dilution is projected to be approximately 12-13%.

Stephen Schwarzman, CEO, said, "We believe the decision to convert will make it significantly easier for both domestic and international investors to own our stock and should drive greater value for all of our shareholders over time."

For the first-quarter, distributable earnings were $538 million or $0.44 per unit, up 7% year-over-year. Fee related earnings were $374 million or $0.31 per unit, up 11%. Net income per common unit was $0.71, an increase of 34% over prior year. On average, 13 analysts polled by Thomson Reuters expected the company to report profit per share of $0.53 for the quarter. Analysts' estimates typically exclude special items.

First-quarter total revenues were $2.03 billion, up 14% from prior year. Total investment income rose 9% to $1.15 billion. Total Assets Under Management was $511.8 billion, up 14% from previous year.

Blackstone has declared a quarterly distribution of $0.37 per common unit to record holders of common units at the close of business on April 29, 2019. This distribution will be paid on May 6, 2019.

Shares of Blackstone were up more than 3% in pre-market trade on Thursday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement. Supermarket chain Wegmans Food Markets, Inc. is recalling select Valencia oranges, lemons, and various other products containing fresh lemon citing potential contamination with Listeria monocytogenes, the U.S. Food and Drug Administration announced. The recall was initiated after Wegmans' lemons and oranges supplier Freshouse Produce LLC, issued a recall of its supplies. A California court ruled that Uber and Lyft must classify their drivers as employees in a preliminary injunction issued on Monday. However, the court has stayed the injunction for 10 days to allow the ride-hailing service providers to appeal the decision.
Follow RTT